Factors that influence therapeutic compliance in osteoporosis;Factures que influyen en el cumplimiento terapéutico en la osteoporosis

Revista Espanola de Enfermedades Metabolicas Oseas

Volumn 15, Issue 3, 2006, Pages 44-46

  Guanabens N ^a  

^a HOSPITAL CLÍNIC   (Spain)

Author keywords

Compliance; Osteoporosis

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; COLECALCIFEROL; RALOXIFENE; VITAMIN D;

CLINICAL PRACTICE; COMORBIDITY; DEMOGRAPHY; ECONOMIC ASPECT; HUMAN; OSTEOPOROSIS; PATIENT COMPLIANCE; REVIEW; SOCIAL ASPECT;

EID: 33746588693     PISSN: 11328460     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1132-8460(06)75260-6     Document Type: Review

References (18)

1. World Health Organization. Adherence to long-term therapies. Evidence for action. Ginebra: WHO Library; 2003.
2. Claxton AJ, Cramer J, Pierce C. A systematic review of the association between dose regimens and medication compliance. Clin Ther. 2001;23:1296-310.
3. Houston Miller N. Compliance with treatment regimens in chronic assymptomatic diseases. Am J Med. 1997;102:43-9.
4. Yood RA, Emani S, Reed JI, Lewis BE, Charpentier M, Lydick E. Compliance with pharmacologic therapy for osteoporosis. Osteoporos Int. 2003;14:965-8.
5. Anónimo. The adherence Gap: Why osteoporosis patients don't continue with treatment. International Osteoporosis Foundation, 2005. Disponible en: www.osteofound.org/publications/adherence_gap_report.html
6. Caro JJ, Ishak KJ, Huybrechts KF, Raggio G, Naujoks C. The impact of compliance with osteoporosis therapy on fracture rates in actual practice. Osteoporos Int. 2004;15:1003-8.
7. Ritcher A, Anton SF, Koch P, Dennett SL. The impact of reducing dose frequency on health outcomes. Clin Ther. 2003;25:2307-35.
8. Tashkin DP. Multiple dose regimens. Impact on compliance. Chest. 1995;107 Supl:176S-82S.
9. Boccuzzi SJ, Foltz SH, Omar MA, Kahler KH. Assessment of adherence and persistence with daily and weekly dosing regimens of oral bisphosphonates. Osteoporos Int. 2005;16 Supl 3:S3.
10. Cramer JA, Amonkar MM, Hebborn A, Altman R. Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis. Curr Med Res Opin. 2005;21:1453-60.
11. Recker RR, Gallagher R, MacCosbe PE. Effect of dosing frequency on bisphosphonate medication adherence in a large longitudinal cohort of women. Mayo Clin Proc. 2005;80:856-61.
12. McCombs JS, Thiebaud P, McLaughlin-Miley C, Shi J. Compliance with drug therapies for the treatment and prevention of osteoporosis. Maturitas. 2004;48:271-87.
13. Clowes JA, Peel NFA, Eastell R. The impact of monitoring on adherence and persistence with antiresorptive treatment for postmenopausal osteoporosis: A randomized controlled trial. J Clin Endocrinol Metab. 2004;89:1117-23.
14. Farrerons J, Malouf J, Longobardi V, Laiz YA. Cumplimiento terapéutico de los suplementos de vitamina D. REEMO. 2005;14 Supl 1:32-4.
15. Jackson RD, LaCroix AZ, Gass M, Wallace RB, Robbins J, Lewis CE, et al. Calcium plus vitamin D supplementation and the risk of fractures. N Engl J Med. 2006;354:669-83.
16. Ros I, Guañabens N, Codina C, Peris P, Roca M, Monegal A, et al. Análisis preliminar de la adherencia al tratamiento de la osteoporosis. Comparación de distintos métodos de evaluación. REEMO. 2002;11:92-6.
17. Simon JA, Lewiecki EM, Smith ME, Petruschke PA, Wang L, Palmisano JJ. Patient preference for once-weekly alendronate 70 mg versus once-daily alendronate 10 mg: A multicenter, randomized, open-label, crossover study. Clin Ther. 2002;24:1871-86.
18. Kendler D, Kung AWC, Fuleihan Gel-H, González-González JC, Gaines KA, Verbruggen N, et al. Patients with osteoporosis prefer once weekly to once daily dosing with alendronate. Maturitas. 2004;48:243-51.